Tivoli Therapeutics Signs MOU with Arich Enterprise

Today, Tivoli Therapeutics is proud to announce the signing of a Memorandum of Understanding (MOU) with Arich Enterprise.

This partnership marks an important step in exploring collaboration opportunities in drug distribution, commercial promotion, and future strategic investment. By combining Tivoli’s strong pharmaceutical distribution network and regulatory expertise with Arich’s market presence, we aim to create greater value for patients and healthcare providers across the region.

At Tivoli, our mission has always been clear: to deliver high-quality therapeutic and healthcare products at competitive prices. With this MOU, we are building the foundation for long-term cooperation that will strengthen supply chains, enhance market access, and open doors for innovative healthcare solutions.

We look forward to a future of mutual growth and shared success with Arich Enterprise.